Our Annual Biotech Review/Preview with STAT’s Adam Feuerstein

Episode Summary

Executive Summary: Adam Feuerstein and Daniel Levine review biotech’s 2019 highs and lows, highlighting a late-year stock rally, major approvals like Vertex’s Trikafta and Novartis’s Zolgensma, Biogen’s controversial Alzheimer’s drug resurgence, and Amarin’s label win. They look ahead to 2020 themes: drug launches, FDA leadership, M&A, pricing politics, and emerging off-the-shelf cell therapy data.

Main Topics: Biotech market performance in 2019 (Priority: 5/5): Feuerstein argues biotech spent most of 2019 trading sideways and underperforming, but surged sharply in the fourth quarter, driving strong one-year returns across biotech indices. Major drug approvals and FDA behavior (Priority: 5/5): The conversation centers on standout approvals such as Trikafta and Zolgensma, plus a pattern of the FDA approving some drugs earlier than expected near year-end. Biogen’s aducanumab controversy (Priority: 5/5): Biogen’s revived Alzheimer’s program is framed as one of the year’s most surprising stories, with substantial skepticism about the claimed benefit and major regulatory uncertainty ahead. Drug launches and commercialization in 2020 (Priority: 4/5): Amarin, Intercept, Aimmune, Global Blood Therapeutics, Vertex, and Novartis are cited as important launch stories, with attention on real-world uptake and reimbursement. Leadership at FDA and industry conferences (Priority: 3/5): Scott Gottlieb’s legacy, Stephen Hahn’s low public profile, and the continued draw of JPMorgan San Francisco are discussed as key industry focal points. M&A and sector consolidation (Priority: 4/5): 2019’s unusually strong biotech M&A environment sets expectations for more deal activity, with UniQure singled out as a commonly discussed acquisition target. Drug pricing and election-year politics (Priority: 3/5): Feuerstein suggests drug pricing may be less of a near-term sector overhang than feared, despite its prominence in the 2020 election cycle.

Key Arguments: Biotech’s strongest gains in 2019 came late, with most of the year spent trading sideways and underperforming broader markets. Trikafta and Zolgensma were the most meaningful approvals because they address serious diseases with transformative potential. FDA behavior appeared more flexible at year-end, with several approvals arriving earlier than expected. Biogen’s aducanumab remains highly controversial because many observers do not see clear benefit in the data. Even so, regulatory pressure to approve an Alzheimer’s therapy could outweigh scientific skepticism due to the lack of effective treatments. Drug launches in 2020 will be critical tests of commercial execution, pricing, and reimbursement, especially for expensive or first-in-class therapies. Biogen’s CEO is criticized not only for aducanumab risk but for failing to diversify the company’s pipeline. RNA interference has matured into a durable therapeutic platform, with Alnylam’s success validating the field. M&A remained very strong in 2019 and may continue, but deal expectations are difficult to predict. Off-the-shelf cell therapies are emerging as the next major innovation area in oncology. Drug pricing will matter politically, but may be less destabilizing to biotech stocks than feared earlier in the year.

Data Points: Biotech index performance: XBI up about 49% over the last year - Used to illustrate biotech’s strong late-2019 rally after a weak start to the year. Biotech index range: Various indices up 35% to 40% - Opening framing of the year’s overall sector performance. Drug approvals in 2019: 49 approvals as of December 20 - Compared with the prior year, but still notable for significant therapies. Cystic fibrosis coverage: About 90% of CF mutations - Vertex’s Trikafta expands treatment reach within cystic fibrosis. M&A deal count: 22 deals greater than $500 million - Lyrinc data cited for 2019 biotech deal activity. Average M&A deal count: About 12 deals per year - Used as comparison to show 2019’s unusually high acquisition activity. Total M&A value: $230 billion - Total biotech M&A deal value in 2019, roughly three times the 10-year average. M&A value comparison: About three times the average over the last 10 years - Indicates unusually strong consolidation and capital deployment. GoFundMe target: $100,000 - Fundraising campaign for the Himalayan cataract project mentioned in the sponsor segment. Surgical impact: 4,300 site-saving surgeries - Recent surgeries performed by the Himalayan cataract project in Ethiopia and Eritrea. People affected by preventable blindness: 18 million - Estimate of people in the developing world unable to perform daily tasks because of treatable cataracts.

Pivotal Quotes: "it was a great year" — Adam Feuerstein: On biotech’s 2019 stock performance after a long stretch of sideways trading. "there could be a lot of pressure on the agency to approve an Alzheimer's drug" — Adam Feuerstein: On the tension between scientific skepticism and FDA willingness to approve therapies with limited options. "it is the most expensive medicine today" — Adam Feuerstein: Referring to Novartis’s Zolgensma and the reimbursement challenge for gene therapies.

Implications: Biotech enters 2020 with momentum but also major binary risks: launch execution, FDA decisions, M&A, pricing politics, and breakthrough-cell-therapy data could move stocks and reshape industry expectations.